SEQUELA

Medtech · Private

ELISA-based diagnostic assay for early detection of chronic kidney disease using a novel biomarker

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026

Sector: Medtech
Total capital: $2.9M

Federal grants: $2.9M; 3 awards · 2015–2017; Rank in peer group#85 of 112
Private capital raised: None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts: None on recordNo federal contract awards found.
Granted patents: 0; 2 pending

Capital timeline

Latest events

Jul 2017Federal grantHealth and Human S · Phase II · Novel Assay To Detect Chronic Kidney Disease$933K
Jul 2016Federal grantHealth and Human S · Phase II · Novel Assay To Detect Chronic Kidney Disease$965K
Aug 2015Federal grantHealth and Human S · Phase II · Novel Assay To Detect Chronic Kidney Disease$989K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 112 peers

Line = median

Medtech · Instrument

Federal grantsBelow median

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

USPTO · 0 granted of 2

Aug 26, 2021PendingBiomarker, Methods, And Compositions Thereof For Evaluation Or Management Of Kidney Function Or Diagnosing Or Aid In Diagnosing Kidney Dysfunction Or Kidney DiseaseUSPTOApplication 17160661
PendingBiomarker, Methods, And Compositions Thereof For Evaluation Or Management Of Kidney Function Or Diagnosing Or Aid In Diagnosing Kidney Dysfunction Or Kidney DiseaseUSPTOApplication PCTUS2021015391

VYNANCE TECHNOLOGIES, LLCSimilar federal contract value in Medtech · null in contracts
Plasmology4, Inc.Similar federal contract value in Medtech · null in contracts
GOBA, LLCSimilar federal contract value in Medtech · null in contracts
Nanox Imaging plc.Similar federal contract value in Medtech · null in contracts
ASC Rodgers Park LLCSimilar federal contract value in Medtech · null in contracts
CELSENSE, INC.Similar federal contract value in Medtech · null in contracts

Regulatory activity · Medtech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.